Pooled HSPs, including gp96 from established murine myeloma cell lines, showed promise as an off-the-shelf vaccine effectively treating mice with large myeloma tumor burdens with HSP combined with anti-B7H1 or anti–IL-10 monoclonal antibodies (48). This evidence concerns the gene HSP90B1 and plasma cell myeloma.